Mira Pharmaceuticals, INC

Mira Pharmaceuticals received a notice from Nasdaq indicating it no longer meets the minimum $1 bid price requirement, with 180 days to regain compliance.

Mira Pharmaceuticals announced positive preclinical study results for its oral drug candidate, MIRA-55, showing favorable bioavailability and distribution for chronic inflammatory pain treatment.

Mira Pharmaceuticals announced positive preclinical study results for its oral drug candidate SKNY-1, showing favorable bioavailability, brain penetration, and potential for once-daily dosing for obesity and addiction.

MIRA Pharmaceuticals announced new preclinical data showing Mira-55 has a distinct mechanism of action and anxiolytic activity compared to THC.

MIRA Pharmaceuticals announced the submission of its Phase 2a clinical trial protocol for Ketamir-2 to the FDA for treating chemotherapy-induced peripheral neuropathy (CIPN).

MIRA Pharmaceuticals has appointed Andriy Mushak as its new fractional Chief Financial Officer, effective June 6, 2026.

MIRA Pharmaceuticals reports a decrease in net loss for Q1 2026 compared to the prior year, driven by lower operating expenses, while advancing its drug candidates.

MIRA Pharmaceuticals reports a significant increase in assets and equity driven by the SKNY acquisition, while continuing clinical trials for its drug candidates.

MIRA Pharmaceuticals reports significant cash burn and Nasdaq non-compliance, raising substantial doubt about its ability to continue as a going concern, despite advancing its neuroscience drug pipeline.

MIRA Pharmaceuticals announces Q1 2025 results, highlighting progress in Ketamir-2 clinical trials and a planned acquisition of SKNY Pharmaceuticals to expand its drug development pipeline.

MIRA Pharmaceuticals reported a net loss of $5.45 million for the nine months ended September 30, 2024, while advancing the development of its lead drug candidate, MIRA-55.

MIRA Pharmaceuticals has filed an amended quarterly report, disclosing the discovery of a new lead drug candidate, MIRA-55, and ongoing financial challenges.

MIRA Pharmaceuticals reported significant net losses for 2025, raising going concern doubts, while advancing its drug candidates Ketamir-2, MIRA-55, and SKNY-1 through clinical and preclinical stages.

MIRA Pharmaceuticals files an amendment to its annual report on Form 10-K to include the consent of Salberg & Company P.A.

MIRA Pharmaceuticals files an amendment to its annual report on Form 10-K to include a policy regarding the recovery of erroneously awarded compensation.

MIRA Pharmaceuticals files its 10-K for the year ended December 31, 2024, detailing financial results, pipeline advancements, and a planned acquisition of SKNY Pharmaceuticals.

MIRA Pharmaceuticals' 10-K filing outlines its capital structure, governance, and the development status of its neuroscience programs, including Ketamir-2 and MIRA-55.

MIRA Pharmaceuticals CEO Erez Aminov received a grant of 83,500 fully vested restricted stock units, convertible to common stock.

MIRA Pharmaceuticals Director Denil Nanji Shekhat acquired 22,378 shares of common stock as compensation for the acquisition of SKNY Pharmaceuticals, Inc.

MIRA Pharmaceuticals CEO Erez Aminov acquired 2,685,456 restricted common shares as compensation for the company's acquisition of SKNY Pharmaceuticals, Inc.

MIRA Pharmaceuticals' CEO, Erez Aminov, had 300,000 stock options repriced to an exercise price of $1.38, aligning with the recent closing stock price.

MIRA Pharmaceuticals CEO Erez Aminov acquired 62,500 shares of common stock at $1.37 per share, increasing his direct beneficial ownership to 844,700 shares.

Director Matthew Whalen of Mira Pharmaceuticals was granted 25,000 stock options with a vesting schedule over one year.

MIRA Pharmaceuticals, Inc. has issued a proxy statement detailing its upcoming virtual Annual Meeting of Shareholders on September 11, 2026, where key proposals including director elections and auditor ratification will be addressed.

MIRA Pharmaceuticals seeks stockholder approval for a merger with SKNY Pharmaceuticals, creating a biopharma company focused on novel therapeutics for smoking cessation, obesity, pain, and cognitive impairment.

MIRA Pharmaceuticals, Inc. has filed a Definitive Proxy Statement with the SEC.

MIRA Pharmaceuticals, Inc. files a definitive proxy statement with the SEC.

MIRA Pharmaceuticals is holding its annual meeting of stockholders on September 12, 2024, to vote on the election of directors, ratification of the auditor, amendments to the 2022 Omnibus Incentive Plan, and adjournment if necessary.